Saturday, January 28, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

DTRA Contracts for Botulinum Neurotoxin Countermeasures Research

by Global Biodefense Staff
February 20, 2014

The Defense Threat Reduction Agency (DTRA) this week announced intentions to award three contracts in support of “Medical Countermeasures for Botulinum Neurotoxin Intoxication Focused on Therapeutics and Neuroregenerative Medicines”.

DTRA has established a multicenter program in which directed research projects are submitted, evaluated and selected to sponsor a network of collaboration amongst researchers. Under the multicenter collaboration, the following three proposals were selected for funding, to be administered in coordination with US Army Medical Research Institute of Chemical Defense (USAMRICD) collaborators:

Montclair State University: MSU will contribute to the botulinum drug discovery effort by synthesizing small molecule drug candidates for treatment of botulinum toxin exposure and optimizing their pharmaceutical properties. First year of research cost is estimated at $428,737. Total five year proposal cost is $2,515,123 

UMass Dartmouth: UMD will support the efforts at the USAMRICD by performing high throughput screening of natural product and small molecule libraries. First year of research cost is estimated at $275,044. Total five year proposal cost is $2,876,104 

Ossianix University: Ossianix will provide an alternative to traditional inhibitors by developing small single chain shark antibodies (VNRS) as potential inhibitors of LC catalytic activity. Ossianix first year of research cost is estimated at $214,608. Total five year proposal cost is $1 Million. 

This consortium type research is under the Memorandum of Agreement (MOA) between DTRA and USAMRICD.  

Source: FBO.gov

Tags: AwardsBotulinum NeurotoxinDefense Threat Reduction AgencyUSAMRICD

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC